Kiora Pharmaceuticals (NASDAQ:KPRX) Trading Down 7.9%

Shares of Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) were down 7.9% during mid-day trading on Wednesday . The company traded as low as $0.50 and last traded at $0.51. Approximately 187,369 shares were traded during mid-day trading, a decline of 87% from the average daily volume of 1,417,318 shares. The stock had previously closed at $0.55.

Analysts Set New Price Targets

Separately, HC Wainwright reiterated a “buy” rating on shares of Kiora Pharmaceuticals in a research note on Wednesday, March 27th.

Kiora Pharmaceuticals Trading Down 7.9 %

The business has a fifty day moving average price of $0.63 and a 200 day moving average price of $0.60.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the business. Boothbay Fund Management LLC acquired a new position in shares of Kiora Pharmaceuticals during the fourth quarter valued at $40,000. Dimensional Fund Advisors LP acquired a new position in shares of Kiora Pharmaceuticals during the first quarter valued at $41,000. Acadian Asset Management LLC acquired a new position in shares of Kiora Pharmaceuticals during the first quarter valued at $70,000. Citadel Advisors LLC acquired a new position in shares of Kiora Pharmaceuticals during the fourth quarter valued at $49,000. Finally, Renaissance Technologies LLC acquired a new position in Kiora Pharmaceuticals during the first quarter worth about $58,000. 76.97% of the stock is owned by institutional investors and hedge funds.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.